CA2890835C - Factor viii-derived peptides for use in the treatment of haemophilia a - Google Patents
Factor viii-derived peptides for use in the treatment of haemophilia a Download PDFInfo
- Publication number
- CA2890835C CA2890835C CA2890835A CA2890835A CA2890835C CA 2890835 C CA2890835 C CA 2890835C CA 2890835 A CA2890835 A CA 2890835A CA 2890835 A CA2890835 A CA 2890835A CA 2890835 C CA2890835 C CA 2890835C
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- seq
- lys
- glu
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1220328.7 | 2012-11-12 | ||
| GBGB1220328.7A GB201220328D0 (en) | 2012-11-12 | 2012-11-12 | Peptides |
| GB1316660.8 | 2013-09-19 | ||
| GBGB1316660.8A GB201316660D0 (en) | 2013-09-19 | 2013-09-19 | Peptides |
| PCT/IB2013/060060 WO2014072958A1 (en) | 2012-11-12 | 2013-11-11 | Peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2890835A1 CA2890835A1 (en) | 2014-05-15 |
| CA2890835C true CA2890835C (en) | 2021-11-23 |
Family
ID=49627013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2890835A Active CA2890835C (en) | 2012-11-12 | 2013-11-11 | Factor viii-derived peptides for use in the treatment of haemophilia a |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20150306192A1 (enExample) |
| EP (1) | EP2917232B1 (enExample) |
| JP (1) | JP6247696B2 (enExample) |
| KR (1) | KR102165486B1 (enExample) |
| CN (1) | CN104903347B (enExample) |
| AU (1) | AU2013343024B2 (enExample) |
| BR (1) | BR112015010625B1 (enExample) |
| CA (1) | CA2890835C (enExample) |
| CY (1) | CY1119164T1 (enExample) |
| DK (1) | DK2917232T3 (enExample) |
| EA (1) | EA036483B1 (enExample) |
| ES (1) | ES2626881T3 (enExample) |
| HR (1) | HRP20170794T1 (enExample) |
| HU (1) | HUE033586T2 (enExample) |
| IL (1) | IL238627B (enExample) |
| IN (1) | IN2015DN03814A (enExample) |
| LT (1) | LT2917232T (enExample) |
| MX (1) | MX350777B (enExample) |
| MY (1) | MY176708A (enExample) |
| NZ (1) | NZ708812A (enExample) |
| PH (1) | PH12015501033B1 (enExample) |
| PL (1) | PL2917232T3 (enExample) |
| PT (1) | PT2917232T (enExample) |
| RS (1) | RS56069B1 (enExample) |
| SG (1) | SG11201503657UA (enExample) |
| SI (1) | SI2917232T1 (enExample) |
| WO (1) | WO2014072958A1 (enExample) |
| ZA (1) | ZA201503127B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018127830A1 (en) | 2017-01-04 | 2018-07-12 | Apitope International Nv | S-arrestin peptides and therapeutic uses thereof |
| US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| EP3715374A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
| GB201909774D0 (en) * | 2019-07-08 | 2019-08-21 | Apitope Tech Bristol Limited | Method |
| WO2022063887A1 (en) | 2020-09-23 | 2022-03-31 | Ablevia Biotech Gmbh | Compound for increasing the efficacy of factor viii replacement therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1918298T3 (da) | 2000-08-21 | 2010-11-29 | Apitope Technology Bristol Ltd | Peptid |
| WO2002060917A2 (en) * | 2000-12-01 | 2002-08-08 | Regents Of The University Of Minnesota | Method to treat hemophilia |
| FR2842812A1 (fr) * | 2002-07-26 | 2004-01-30 | Pf Medicament | Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une reponse de type ctl antitumorale ou anti-infectueuse |
| JP2006188507A (ja) * | 2004-12-10 | 2006-07-20 | Tokyo Univ Of Agriculture & Technology | 蛋白質の溶解度向上方法 |
| ES2386462T3 (es) * | 2005-10-28 | 2012-08-21 | Boehringer Ingelheim International Gmbh | Ensayo de la actividad NS2/3 del virus de la hepatitis C |
| GB0723712D0 (en) * | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
| GB0801513D0 (en) * | 2008-01-28 | 2008-03-05 | Circassia Ltd | Peptides from factor VIII |
| GB0908515D0 (en) * | 2009-05-18 | 2009-06-24 | Apitope Technology Bristol Ltd | Peptide |
| CA2780763A1 (en) * | 2009-11-13 | 2011-05-19 | Puget Sound Blood Center | Factor viii b cell epitope variants having reduced immunogenicity |
| US8969524B2 (en) * | 2010-10-27 | 2015-03-03 | Baxter International Inc. | FVIII peptides for immune tolerance induction and immunodiagnostics |
-
2013
- 2013-11-11 PL PL13795002T patent/PL2917232T3/pl unknown
- 2013-11-11 SG SG11201503657UA patent/SG11201503657UA/en unknown
- 2013-11-11 CA CA2890835A patent/CA2890835C/en active Active
- 2013-11-11 MX MX2015005973A patent/MX350777B/es active IP Right Grant
- 2013-11-11 CN CN201380069078.2A patent/CN104903347B/zh not_active Expired - Fee Related
- 2013-11-11 DK DK13795002.8T patent/DK2917232T3/en active
- 2013-11-11 EP EP13795002.8A patent/EP2917232B1/en active Active
- 2013-11-11 SI SI201330663A patent/SI2917232T1/sl unknown
- 2013-11-11 BR BR112015010625-0A patent/BR112015010625B1/pt not_active IP Right Cessation
- 2013-11-11 WO PCT/IB2013/060060 patent/WO2014072958A1/en not_active Ceased
- 2013-11-11 PT PT137950028T patent/PT2917232T/pt unknown
- 2013-11-11 EA EA201590927A patent/EA036483B1/ru unknown
- 2013-11-11 MY MYPI2015001224A patent/MY176708A/en unknown
- 2013-11-11 RS RS20170542A patent/RS56069B1/sr unknown
- 2013-11-11 NZ NZ708812A patent/NZ708812A/en not_active IP Right Cessation
- 2013-11-11 LT LTEP13795002.8T patent/LT2917232T/lt unknown
- 2013-11-11 JP JP2015541291A patent/JP6247696B2/ja not_active Expired - Fee Related
- 2013-11-11 US US14/441,923 patent/US20150306192A1/en not_active Abandoned
- 2013-11-11 HR HRP20170794TT patent/HRP20170794T1/hr unknown
- 2013-11-11 HU HUE13795002A patent/HUE033586T2/hu unknown
- 2013-11-11 KR KR1020157012787A patent/KR102165486B1/ko not_active Expired - Fee Related
- 2013-11-11 ES ES13795002.8T patent/ES2626881T3/es active Active
- 2013-11-11 IN IN3814DEN2015 patent/IN2015DN03814A/en unknown
- 2013-11-11 AU AU2013343024A patent/AU2013343024B2/en not_active Ceased
-
2015
- 2015-05-04 IL IL238627A patent/IL238627B/en active IP Right Grant
- 2015-05-07 ZA ZA2015/03127A patent/ZA201503127B/en unknown
- 2015-05-08 PH PH12015501033A patent/PH12015501033B1/en unknown
-
2017
- 2017-05-31 CY CY20171100568T patent/CY1119164T1/el unknown
-
2021
- 2021-04-23 US US17/239,251 patent/US20210346476A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2227488B3 (en) | Fviii peptides and their use in tolerising haemophiliacs | |
| US20210346476A1 (en) | Modified FVIII Apitope Peptides | |
| EP2465523B1 (en) | FVIII-derived peptides and their use in tolerising haemophiliacs | |
| HK1209138B (en) | Factor viii-derived peptides for use in the treatment of haemophilia a | |
| HK1172240A (en) | Fviii-derived peptides and their use in tolerising haemophiliacs | |
| HK1172240B (en) | Fviii-derived peptides and their use in tolerising haemophiliacs | |
| HK1144292B (en) | Fviii peptides and their use in tolerising haemophiliacs | |
| HK1173358B (en) | Fviii-derived peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180925 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260107 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260313 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260313 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260420 |